Results 31 to 40 of about 20,735 (212)

TBVAC2020 : advancing tuberculosis vaccines from discovery to clinical development [PDF]

, 2017
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment.
Aagaard, Claus, Andersen, Peter, Bastian, Max, Britton, Warwick, Brosch, Roland, Caccamo, Nadia, Charneau, Pierre, Cho, Sang Nae, Christensen, Dennis, Counoupas, Claudio, Dockrell, Hazel M., Drager, Nick, Gilleron, Martine, Goletti, Delia, Gordon, Stephen, Grooten, Johan, Guilhot, Christophe, Ho, Mei Mei, Huygen, Kris, Inchauspe, Genevieve, Kallert, Stephanie, Kaufmann, Stefan H. E., Lee, Hyejon, Lindenstrom, Thomas, Locht, Camille, Maertzdorf, Jeroen, Marie-Ange Demoitie, Demoitie, Mascart, Francoise, McShane, Helen, Neyrolles, Olivier, Nieuwenhuizen, Natalie, Nisini, Roberto, Ottenhoff, Tom H. M., Patel, Brij, Peixoto, Antonio, Perrie, Yvonne, Romano, Marta, Roordink, Danielle, Ruhwald, Morten, Shin, Sung Jae, Spertini, François, Stenger, Steffen, TBVAC2020 Consortium, Theung Long, Stephane Leung, Thole, Jelle, Tima, Hermann Giresse, Triccas, Jamie, Vergne, Isabelle, Verreck, Frank A. W., Weiner, January, Williams, Ann   +50 more
core   +5 more sources

Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand

Vaccine: X, 2023
Background: In Thailand, early vaccination initiatives for SARS-CoV-2 relied on CoronaVac (Sinovac Life Sciences) and ChAdOx1 (Oxford–AstraZeneca) vaccines. However, the data of immunogenicity of these two vaccines in Thai populations is limited.
Sayamon Hongjaisee, Kriangkrai Chawansuntati, Patumrat Sripan, Kritsadee Rattanathammethee, Supachai Sakkhachornphop, Romanee Chaiwarith, Tavitiya Sudjaritruk, Khuanchai Supparatpinyo, Jiraprapa Wipasa   +8 more
doaj   +1 more source

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial [PDF]

, 2023
Background: There are limited data on the immunogenicity of coronavirus disease 2019 (COVID-19) vaccines in African populations. Here we report the immunogenicity and safety of the ChAdOx1 nCoV-19 (AZD1222) vaccine from a phase 1/2 single-blind ...
Agoti, Charles, Aliyan, Nadia, Bejon, Philip, Boyd, Amy, Cheruiyot, Stanley, Davies, Alun, Douglas, Alexander, Etyang, Anthony, Gilbert, Sarah, Gitonga, John, Hamaluba, Mainga, Hill, Adrian, Kamau, Naomi, Karanja, Henry, Kasera, Kadondi, Kutima, Bernadette, Lambe, Teresa, Mauncho, Cynthia, Mturi, Neema, Mugo, Daisy, Mumba, Noni, Munene, Marianne, Mwatasa, Mwaganyuma, Namayi, Roselyne, Nduati, Eunice, Ngetsa, Caroline, Njau, Irene, Nyaguara, Amek, Nyagwange, James, Ochola-Oyier, Lynette, Oloo, Elizaphan, Omuoyo, Donwilliams, Orindi, Benedict, Pollard, Andrew, Sang, Samuel, Tsofa, Benjamin, Warimwe, George, Wright, Daniel   +37 more
core   +2 more sources

Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination [PDF]

BMJ Case Reports, 2021
The global COVID-19 pandemic remains challenging with efforts for community vaccination the primary strategy to control transmission and disease sequalae in the mid to long term. While several candidate vaccines have been approved for use, there is an ongoing discussion regarding potential vaccine-related adverse events.
Phillip Crane, Chiew Wong, Nilesh Mehta, Peter Barlis   +3 more
openaire   +2 more sources

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity

Vaccines, 2023
This study investigated the immunogenicity of, and reactogenicity to, the ChAdOx1 nCoV-19 vaccine according to pre-existing adenovirus immunity. Individuals scheduled for COVID-19 vaccination were prospectively enrolled in a tertiary hospital with 2400 ...
Jinnam Kim, Changhyup Kim, Jung Ah Lee, Se Ju Lee, Ki Hyun Lee, Jung Ho Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Joon-Sup Yeom, Young Goo Song, Jun Yong Choi   +11 more
doaj   +1 more source

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events:A population-based cohort study of 46 million adults in England [PDF]

, 2022
BACKGROUND: Thromboses in unusual locations after the Coronavirus Disease 2019 (COVID-19) vaccine ChAdOx1-S have been reported, although their frequency with vaccines of different types is uncertain at a population level.
,, Whiteley, William N
core   +3 more sources

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study

BMC Infectious Diseases, 2022
Background Due to safety signals after vaccination with COVID-19 vector vaccines, several states recommended to complete the primary immunization series in individuals having received one dose of ChAdOx1 (AstraZeneca) with an mRNA vaccine.
Lisette Warkentin, Nikoletta Zeschick, Thomas Kühlein, Philipp Steininger, Klaus Überla, Isabelle Kaiser, Christine Gall, Maria Sebastião, Susann Hueber   +8 more
doaj   +1 more source

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +1 more source

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland [PDF]

, 2022
We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis.
Ashley Akbari, Ronan Lyons
core   +1 more source

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

Cell Reports, 2023
Summary: Therapeutic neoantigen cancer vaccines have limited clinical efficacy to date. Here, we identify a heterologous prime-boost vaccination strategy using a self-assembling peptide nanoparticle TLR-7/8 agonist (SNP) vaccine prime and a chimp ...
Ramiro A. Ramirez-Valdez, Faezzah Baharom, Ahad Khalilnezhad, Sloane C. Fussell, Dalton J. Hermans, Alexander M. Schrager, Kennedy K.S. Tobin, Geoffrey M. Lynn, Shabnam Khalilnezhad, Florent Ginhoux, Benoit J. Van den Eynde, Carol Sze Ki Leung, Andrew S. Ishizuka, Robert A. Seder   +13 more
doaj   +1 more source